Corrections
What we got wrong, and what we did about it
WeighLab models the cost of medical decisions, so being wrong here has a cost. When we publish a claim that turns out to be incorrect, we fix it and record it below — what we said, what it says now, and how we established the right answer. Entries are never removed.
Prices move constantly, and a provider changing its own price is not an error on our part. Those are re-verifications, dated on each provider's review page rather than logged here. This page is for claims that were wrong when we made them.
Spotted something? Tell us and we will re-check it — see how to reach the desk.
Care Bare Rx review and cost rankings
What we published. We published Care Bare Rx at $185/mo for compounded semaglutide and $293/mo for tirzepatide. Those are the rates for paying twelve months up front. The month-to-month price — what most people actually pay — was missing from the review entirely.
What it says now. Month to month is $199 for semaglutide and $299 for tirzepatide, and the review now leads with those. It also notes something worth knowing before you commit: Care Bare Rx's three-month plan costs MORE per month than paying monthly, on both medications. Their prices are not published on their public site, so this came from working through their sign-up form.
Gala Health review and the cheapest-semaglutide rankings
What we published. We recorded Gala Health's $179/mo price as a compounded semaglutide price, and listed their tirzepatide price as undisclosed. That put Gala into our cheapest-semaglutide rankings for a medication they do not sell in compounded form.
What it says now. Gala's own product cards label that price “Compounded GLP-1/GIP — incl. tirzepatide”. A GLP-1/GIP dual agonist is tirzepatide, and Gala sells no compounded semaglutide at all — semaglutide is available from them only as brand-name Ozempic at $1,299/mo. The $179 is now recorded against tirzepatide, where it belongs, and Gala no longer appears in our compounded-semaglutide rankings for a product it does not sell. The yearly-subscription term was recorded correctly the first time and is unchanged.
CoreAge Rx review and every ranking that prices it
What we published. We published CoreAge Rx at $149/mo for compounded semaglutide and $349/mo for tirzepatide. CoreAge charges $99 and $149, and had been advertising those figures on its own product pages and its own sign-up funnel — so our prices were 50% and 134% above what the provider actually charges.
What it says now. Both figures now match CoreAge's published prices, checked on two separate surfaces of their site on the same day. Their terms are explicit — one price at every dose, no membership fee, and a refill price that does not change — so these are month-to-month rates rather than an introductory or prepaid rung. Our value score did not move: it had been calculated on the real price all along, and only the displayed figures were out of date.
Trimi Health review and cost rankings
What we published. We published Trimi Health at $99/mo for compounded semaglutide and $125/mo for tirzepatide, and ranked it near the top of our cheapest-provider rankings on those figures. Both were Trimi's annual-prepay rates — payable as $1,188 and $1,500 up front — not what you pay month to month.
What it says now. Read off Trimi's own four-rung price table, the month-to-month rates are $175 and $235. The review now carries those figures and names the annual rate as the prepay rung it is. Because our value score is derived from the price, the score fell from 85 to 78 and the provider moved down our rankings accordingly. We have added Trimi to the build check that compares a filed price against a provider's published term ladder, so this cannot recur on this row.
Orforglipron (Foundayo) explainer
What we published. The article said orforglipron “has not received FDA approval” and “remains in the regulatory review pipeline”. That was wrong when it was published on 3 August 2026, and our own provider data contradicted it the following day.
What it says now. FDA approved orforglipron as Foundayo under application NDA 220934 on 1 April 2026, with a further supplement approved on 4 August 2026. We verified this in FDA's own Drugs@FDA record rather than a press summary, corrected the article body and its FAQ, and added the FDA record as a cited source.
Provider reviews — regulatory disclosure
What we published. Two providers we link to had received FDA warning letters that were public from 3 March 2026, and our reviews of them did not say so.
What it says now. Both now carry the disclosure on every surface that profiles them. We built a monthly screen of the full FDA warning-letter register so a new letter is caught in weeks rather than by chance, and confirmed each match by the domain named inside the letter itself. A warning letter is a fact we disclose; it does not by itself remove a provider from the board.
Provider reviews — summary sentences
What we published. 256 provider summaries were cut off mid-sentence, ending in an ellipsis. The truncated text also reached the structured data search engines and AI assistants read.
What it says now. Every affected summary was rewritten to a complete sentence from the underlying research, the generator that produced them was fixed, and a build check now blocks any unfinished sentence from shipping.
How we source and check everything else is set out in our editorial policy and methodology.